4//SEC Filing
MARINO JAMES J 4
Accession 0001179110-19-010682
CIK 0001130598other
Filed
Sep 25, 8:00 PM ET
Accepted
Sep 26, 6:22 PM ET
Size
16.3 KB
Accession
0001179110-19-010682
Insider Transaction Report
Form 4
MARINO JAMES J
Director
Transactions
- Purchase
Warrant (right to purchase)
2019-09-25+5,000→ 5,000 totalExercise: $0.11From: 2019-09-25Exp: 2022-12-31→ Series A Convertible Preferred Stock (5,000 underlying) - Expiration (Short)
Warrant (right to purchase)
2019-09-25−1,472.5→ 0 totalExercise: $0.42From: 2018-05-01→ Series B Convertible Preferred Stock (1,472.5 underlying) - Expiration (Short)
Warrant (right to purchase)
2019-09-25−5,000→ 0 totalExercise: $1.01From: 2018-02-12→ Series A Convertible Preferred Stock (5,000 underlying) - Purchase
Common Stock
2019-09-25$1.60/sh+7,260$11,616→ 16,942 total - Purchase
Warrant (right to purchase)
2019-09-25+1,472.5→ 1,472.5 totalExercise: $0.11From: 2019-09-25Exp: 2022-12-31→ Series B Convertible Preferred Stock (1,472.5 underlying)
Footnotes (6)
- [F1]These warrants were acquired in a public offering, by Onconova Therapeutics, Inc. (the Company), of units which included one share of common stock and one warrant. The public offering price for each unit was $1.01.
- [F2]The warrants were exercisable immediately at an exercise price of $1.01 per 0.1 share of Series A Convertible Preferred Stock and would expire on the later of (i) the one-year anniversary of the date on which theCompany publicly announces through the filing of a Current Report on Form 8-K that a Charter Amendment, increasing the number of available common shares, has been filed with the Secretary of State of the State of Delaware and (ii) the earlier of (A) the one-month anniversary of the date on which the Company publically releases certain topline results of the INSPIRE Pivotal phase 3 trial that compare the overall survival (OS) of patients in the rigosertib group vs the Physician's Choice group, in all patients and in a subgroup of patients with IPSS-R very high risk and (B) December 31, 2019.
- [F3]In connection with a purchase of the Company's common stock on September 25, 2019 the terms of a warrant to purchase Series A preferred stock, previously purchased on February 12, 2018, were amended as follows: (1) the exercise price of the warrant to purchase one share of common stock on an as-exercised and as-converted basis was reduced from $1.01 per 0.1 share of Series A Preferred Stock to $0.10667 per 0.1 share of Series A Preferred Stock which, on an as-converted basis, equals $1.60 per share of common stock, and (2) the expiration date of the warrant was extended to December 31, 2022. The price for amending Series A Preferred Stock Warrants was $0.125 per share (on an as-converted basis per share of common stock).
- [F4]These warrants were acquired in a public offering, by the Company, of units which included one share of common stock and one warrant. The public offering price for each unit was $0.425.
- [F5]The warrants were exercisable immediately at an exercise price of $0.425 per 0.025 share of Series B Convertible Preferred Stock and would expire on the 18-month anniversary of the date on which the Company publicly announced through the filing of a Current Report on Form 8-K that a Charter Amendment, increasing the number of available common shares, has been filed with the Secretary of State of the State of Delaware.
- [F6]In connection with a purchase of the Company's common stock on September 25, 2019 the terms of a warrant to purchase Series B preferred stock, previously purchased on May 1,2018, were amended as follows: (1) the exercise price of the warrant to purchase one share of common stock on an as-exercised and as-converted basis was reduced from $0.425 per 0.025 share of Series B Preferred Stock to $0.10667 per 0.025 share of Series B Preferred Stock which, on an as-converted basis, equals $1.60 per share of common stock, and (2) the expiration date of the warrant was extended to December 31, 2022. The price for amending Series B Preferred Stock Warrants was $0.125 per share (on an as-converted basis per share of common stock).
Documents
Issuer
Onconova Therapeutics, Inc.
CIK 0001130598
Entity typeother
Related Parties
1- filerCIK 0001198578
Filing Metadata
- Form type
- 4
- Filed
- Sep 25, 8:00 PM ET
- Accepted
- Sep 26, 6:22 PM ET
- Size
- 16.3 KB